TY - JOUR
T1 - Combination therapies for precision oncology
T2 - The ultimate whack-a-mole game
AU - Groisberg, Roman
AU - Subbiah, Vivek
N1 - Funding Information:
V. Subbiah reports grants from LOXO Oncology during the conduct of the study and Bayer outside the submitted work, and research funding/grant support for clinical trials (to his institution) from AbbVie, Agensys, Alfa-sigma, Altum, Amgen, Bayer, Berghealth, Blueprint, Boston Biomedical, Boston Pharmaceuticals, D3, Dragonfly Therapeutics, Exelixis, Fujifilm, Idera Pharma, Incyte, InhibRx, Loxo oncology, Medimmune, MultiVir, NCI Cancer Therapy Evaluation Program, National Comprehensive Cancer Network, Novartis, PharmaMar, Pfizer, Takeda, Turning Point Therapeutics, and University of Texas MD Anderson Cancer Center. No disclosures were reported by the other author.
Funding Information:
The authors thank the inspiration from Dr. Emil J. Freireich, MD (1927–2021), father of modern oncology clinical trials who first pioneered combination trials in oncology. V. Subbiah acknowledges support by NIH grant R01CA242845. UT MD Anderson Cancer Center, Clinical Center for Targeted therapy was supported by the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, 1U01 CA180964, NCATS grant UL1 TR000371 (Center for Clinical and Translational Sciences), and the MD Anderson Cancer Center Support Grant (P30 CA016672).
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/5
Y1 - 2021/5
N2 - The single-agent activity of MEK inhibitors in MAPK or CDK4/6 inhibitors in cyclin pathway aberrant tumors has been limited. The combination of trametinib and palbociclib demonstrates safety, tolerability, and clinical activity in a histology-independent manner, representing a therapeutic approach for patients harboring co-occurring aberrations.
AB - The single-agent activity of MEK inhibitors in MAPK or CDK4/6 inhibitors in cyclin pathway aberrant tumors has been limited. The combination of trametinib and palbociclib demonstrates safety, tolerability, and clinical activity in a histology-independent manner, representing a therapeutic approach for patients harboring co-occurring aberrations.
UR - http://www.scopus.com/inward/record.url?scp=85106260794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106260794&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-21-0254
DO - 10.1158/1078-0432.CCR-21-0254
M3 - Article
C2 - 33707180
AN - SCOPUS:85106260794
SN - 1078-0432
VL - 27
SP - 2672
EP - 2674
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -